Lab
Intelligenecg LLC
Intelligenecg LLC was paid $182K by Medicaid between Jul 2018 and Mar 2022, across 47 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 38% of everything it billed.
33Billing provider infoINTELLIGENECG LLC
STILWELL, KS 66085
STILWELL, KS 66085
33aNPI1548611593assigned 06/30/2016
33bProvider typeClinical Medical Laboratory
28Total paid$182K
24GClaims3,501
24DCodes billed47
24AFirst – last monthJul 2018 – Mar 2022
Compared with peers
Next to other Clinical Medical Laboratory providers in Kansas
Rank by total paid#17 of 47
Median peer was paid$64K
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 425 | $57K | |
| 2019 | 1,676 | $89K | |
| 2020 | 798 | $19K | |
| 2021 | 155 | $4K | |
| 2022 | 447 | $13K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 38% | 232 | 228 | $70K |
| 81404 | 10.0% | 72 | 53 | $18K | |
| 81317 | 6.9% | 54 | 49 | $13K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.8% | 200 | 161 | $12K |
| 81408 | 3.5% | 69 | 49 | $6K | |
| 87556 | 2.9% | 234 | 230 | $5K | |
| 87500 | 2.7% | 233 | 229 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.7% | 233 | 229 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.4% | 232 | 228 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.4% | 232 | 228 | $4K |
| 81406 | 2.4% | 70 | 51 | $4K | |
| 81432 | 2.2% | 32 | 30 | $4K |
35 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.2% | 199 | $4K |
| 81334 | 1.9% | 16 | $4K | |
| 81272 | 1.9% | 16 | $3K | |
| 81235 | 1.9% | 16 | $3K | |
| 81236 | 1.8% | 16 | $3K | |
| 81218 | 1.7% | 16 | $3K | |
| 81405 | 1.3% | 54 | $2K | |
| 87186 | <1% | 234 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 203 | $1K |
| 81403 | <1% | 51 | $1K | |
| 81327 | <1% | 15 | $1K | |
| 81240 | <1% | 16 | $892.78 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 230 | $839.40 |
| 81378 | <1% | 14 | $723.42 | |
| 81355 | <1% | 12 | $141.12 | |
| 87088 | <1% | 33 | $45.90 | |
| 81291 | 0% | 30 | $0.00 | |
| 81241 | 0% | 16 | $0.00 | |
| 81307 | 0% | 19 | $0.00 | |
| 81292 | 0% | 19 | $0.00 | |
| 81321 | 0% | 19 | $0.00 | |
| 81401 | 0% | 18 | $0.00 | |
| 81479 | Unlisted molecular pathology procedure | 0% | 74 | $0.00 |
| 81295 | 0% | 19 | $0.00 | |
| 81201 | 0% | 16 | $0.00 | |
| 81242 | 0% | 16 | $0.00 | |
| 81231 | 0% | 30 | $0.00 | |
| 81226 | 0% | 30 | $0.00 | |
| 81209 | 0% | 16 | $0.00 | |
| 81225 | 0% | 30 | $0.00 | |
| 81230 | 0% | 30 | $0.00 | |
| 81227 | 0% | 30 | $0.00 | |
| 81162 | 0% | 19 | $0.00 | |
| 81407 | 0% | 17 | $0.00 | |
| 81298 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOLIVEIRA, MARIO (CEO)